Search research articles
Contact Us
Filters
Showing results (171-180 of 268) with videos related to
Page
of 27
Sort By:
JTO Clinical and Research Reports
|
September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung Cancers
Noura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 13, 2023
Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib
Emily Miao, Jordan E Eichholz, Emily S Lebow, et al.
British Journal of Cancer
|
June 20, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Paola Roa, Valentina Foglizzo, Guilherme Harada, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 14, 2023
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification
Arielle Elkrief, Igor Odintsov, Vladimir Markov, et al.
JCO Precision Oncology
|
April 27, 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
Margherita Ambrosini, Marzia Del Re, Paolo Manca, et al.
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Lancet. Oncology
|
August 19, 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott J Antonia, Hossein Borghaei, Suresh S Ramalingam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Anna F Farago, Long P Le, Zongli Zheng, et al.
Page
of 27
Search research articles
Search
Showing results (171-180 of 268) with videos related to
Sort By:
Page
of 27
JTO Clinical and Research Reports
|
September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung Cancers
Noura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 13, 2023
Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib
Emily Miao, Jordan E Eichholz, Emily S Lebow, et al.
British Journal of Cancer
|
June 20, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Paola Roa, Valentina Foglizzo, Guilherme Harada, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 14, 2023
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification
Arielle Elkrief, Igor Odintsov, Vladimir Markov, et al.
JCO Precision Oncology
|
April 27, 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
Margherita Ambrosini, Marzia Del Re, Paolo Manca, et al.
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Lancet. Oncology
|
August 19, 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott J Antonia, Hossein Borghaei, Suresh S Ramalingam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Anna F Farago, Long P Le, Zongli Zheng, et al.
Page
of 27